Clinical Trial Update: Safety and Tolerability of Rituximab in Neuromyelitis Optica [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and tolerability of rituximab in patients with Neuromyelitis Optica has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neuromyelitis Optica | Phase 1 | Status: COMPLETED